{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:15:27Z","timestamp":1791850527669,"version":"4.3.4"},"reference-count":25,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2004,5,14]],"date-time":"2004-05-14T00:00:00Z","timestamp":1084492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2004,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Gemcitabine\u2010associated thrombotic microangiopathy (TMA) is believed to be very rare, with an estimated incidence rate of 0.015%. Indications for gemcitabine are expanding, and comprehensive characterization of this complication is therefore important.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>The authors performed a retrospective chart review of all cases with gemcitabine\u2010associated TMA diagnosed at Partners Healthcare System (Boston, MA) between January 1997 and February 2002.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Nine patients with gemcitabine\u2010associated TMA were identified. Diagnosis was aided by clinical and laboratory features. Renal biopsy confirmed the diagnosis in two patients. The cumulative incidence of gemcitabine\u2010associated TMA was 0.31% (8 cases among 2586 patients) when only the 8 patients with TMA who were treated at clinics associated with the current study were considered (1 patient with a TMA syndrome was transferred from another institution). The median patient age was 53 years, and the median time to development of a TMA syndrome after the initiation of gemcitabine was 8 months (range, 3\u201318 months), with a cumulative dose ranging from 9 to 56 g\/m<jats:sup>2<\/jats:sup>. New or exacerbated hypertension was a prominent feature in 7 of 9 patients and preceded the clinical diagnosis by 0.5\u201310 weeks. Treatment of TMA included discontinuation of gemcitabine, antihypertensive therapy, plasma exchange, and dialysis. Outcomes are known for all nine patients. Six patients remain alive, whereas three have died of disease progression. No patient died as a direct result of TMA, but two developed kidney failure requiring dialysis, and one developed chronic renal insufficiency.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>In the current series, the largest single\u2010institution study to date, the incidence of gemcitabine\u2010associated TMA was higher than previously reported (0.31% vs. 0.015%). Seven of nine patients developed new or exacerbated hypertension, which could be a useful early identifier of patients with gemcitabine\u2010associated TMA syndromes. Cancer 2004. \u00a9 2004 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.20290","type":"journal-article","created":{"date-parts":[[2004,5,14]],"date-time":"2004-05-14T12:00:46Z","timestamp":1084536046000},"page":"2664-2670","source":"Crossref","is-referenced-by-count":149,"title":["Gemcitabine\u2010associated thrombotic microangiopathy"],"prefix":"10.1002","volume":"100","author":[{"given":"Benjamin D.","family":"Humphreys","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff P.","family":"Sharman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut G.","family":"Rennke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew X.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colm C.","family":"Magee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,6,2]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra020528"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.060003831.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/79.3.511"},{"key":"e_1_2_6_5_2","first-page":"271","volume-title":"Hemolytic uremic syndrome and thrombotic thrombocytopenic purpura","author":"Murgo AJ","year":"1992"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.6.781"},{"key":"e_1_2_6_7_2","first-page":"161","article-title":"Thrombotic microangiopthy in the cancer patient including those induced by chemotherapeutic agents","volume":"24","author":"Murgo AJ","year":"1987","journal-title":"Semin Hematol"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200124070-00002"},{"key":"e_1_2_6_9_2","volume-title":"2001 annual report","author":"Eli Lilly and Company","year":"2002"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2002.35758"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9<2023::AID-CNCR21>3.0.CO;2-2"},{"key":"e_1_2_6_12_2","first-page":"1154","volume-title":"Renal pathology","author":"Remuzzi G","year":"1994"},{"key":"e_1_2_6_13_2","volume-title":"Gemzar\u00ae [product label]","author":"Eli Lilly and Company","year":"2003"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(96)90155-9"},{"key":"e_1_2_6_15_2","first-page":"1058","volume-title":"Renal pathology","author":"D'Agati VD","year":"1994"},{"key":"e_1_2_6_16_2","first-page":"37","article-title":"Hemolytic uremic syndrome in children and arteriolar hypertension","volume":"74","author":"Habib R","year":"1981","journal-title":"Arch Mal Coeur Vaiss"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1979.70"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-197401000-00001"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(82)90748-3"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.4065\/77.4.323"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(99)70194-0"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2003.50058"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2000.00241.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199902270-00009"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2000.17690"},{"key":"e_1_2_6_26_2","first-page":"32","article-title":"Gemcitabine safety overview","volume":"23","author":"Green MR","year":"1996","journal-title":"Semin Oncol"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.20290","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.20290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:27:12Z","timestamp":1760300832000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.20290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6,2]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2004,6,15]]}},"alternative-id":["10.1002\/cncr.20290"],"URL":"https:\/\/doi.org\/10.1002\/cncr.20290","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6,2]]}}}